These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 23816817)

  • 1. Interactions among bone, liver, and adipose tissue predisposing to diabesity and fatty liver.
    Musso G; Paschetta E; Gambino R; Cassader M; Molinaro F
    Trends Mol Med; 2013 Sep; 19(9):522-35. PubMed ID: 23816817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications.
    Cusi K
    Gastroenterology; 2012 Apr; 142(4):711-725.e6. PubMed ID: 22326434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatic steatosis: a mediator of the metabolic syndrome. Lessons from animal models.
    den Boer M; Voshol PJ; Kuipers F; Havekes LM; Romijn JA
    Arterioscler Thromb Vasc Biol; 2004 Apr; 24(4):644-9. PubMed ID: 14715643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Has natural selection in human populations produced two types of metabolic syndrome (with and without fatty liver)?
    Caldwell SH; Ikura Y; Iezzoni JC; Liu Z
    J Gastroenterol Hepatol; 2007 Jun; 22 Suppl 1():S11-9. PubMed ID: 17567458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of bezafibrate in nonalcoholic steatohepatitis model mice with monosodium glutamate-induced metabolic syndrome.
    Sasaki Y; Shimada T; Iizuka S; Suzuki W; Makihara H; Teraoka R; Tsuneyama K; Hokao R; Aburada M
    Eur J Pharmacol; 2011 Jul; 662(1-3):1-8. PubMed ID: 21549692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel drugs in familial combined hyperlipidemia: lessons from type 2 diabetes mellitus.
    Brouwers MC; de Graaf J; van Greevenbroek MM; Schaper N; Stehouwer CD; Stalenhoef AF
    Curr Opin Lipidol; 2010 Dec; 21(6):530-8. PubMed ID: 20739883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel insights into the relationship between nonalcoholic fatty liver disease and osteoporosis.
    Filip R; Radzki RP; Bieńko M
    Clin Interv Aging; 2018; 13():1879-1891. PubMed ID: 30323574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adipose tissue dysfunction in obesity.
    Blüher M
    Exp Clin Endocrinol Diabetes; 2009 Jun; 117(6):241-50. PubMed ID: 19358089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Altered expression of transcription factors and genes regulating lipogenesis in liver and adipose tissue of mice with high fat diet-induced obesity and nonalcoholic fatty liver disease.
    Morgan K; Uyuni A; Nandgiri G; Mao L; Castaneda L; Kathirvel E; French SW; Morgan TR
    Eur J Gastroenterol Hepatol; 2008 Sep; 20(9):843-54. PubMed ID: 18794597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liver fat in the pathogenesis of insulin resistance and type 2 diabetes.
    Yki-Järvinen H
    Dig Dis; 2010; 28(1):203-9. PubMed ID: 20460912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular mechanisms of steatosis in nonalcoholic fatty liver disease.
    Pettinelli P; Obregón AM; Videla LA
    Nutr Hosp; 2011; 26(3):441-50. PubMed ID: 21892559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The genetic basis of obesity and type 2 diabetes: lessons from the new zealand obese mouse, a polygenic model of the metabolic syndrome.
    Joost HG
    Results Probl Cell Differ; 2010; 52():1-11. PubMed ID: 20865367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypoadiponectinemia plays a crucial role in the development of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus independent of visceral adipose tissue.
    Yoneda M; Iwasaki T; Fujita K; Kirikoshi H; Inamori M; Nozaki Y; Maeyama S; Wada K; Saito S; Terauchi Y; Nakajima A
    Alcohol Clin Exp Res; 2007 Jan; 31(1 Suppl):S15-21. PubMed ID: 17331160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic complications of obesity: inflated or inflamed?
    Chandalia M; Abate N
    J Diabetes Complications; 2007; 21(2):128-36. PubMed ID: 17331862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The metabolic syndrome and nonalcoholic fatty liver disease.
    Collantes RS; Ong JP; Younossi ZM
    Panminerva Med; 2006 Mar; 48(1):41-8. PubMed ID: 16633331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review article: non-alcoholic fatty liver disease and osteoporosis--clinical and molecular crosstalk.
    Yilmaz Y
    Aliment Pharmacol Ther; 2012 Aug; 36(4):345-52. PubMed ID: 22730920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The inflammatory C-reactive protein is increased in both liver and adipose tissue in severely obese patients independently from metabolic syndrome, Type 2 diabetes, and NASH.
    Anty R; Bekri S; Luciani N; Saint-Paul MC; Dahman M; Iannelli A; Amor IB; Staccini-Myx A; Huet PM; Gugenheim J; Sadoul JL; Le Marchand-Brustel Y; Tran A; Gual P
    Am J Gastroenterol; 2006 Aug; 101(8):1824-33. PubMed ID: 16790033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abdominal adipose tissue cytokine gene expression: relationship to obesity and metabolic risk factors.
    You T; Yang R; Lyles MF; Gong D; Nicklas BJ
    Am J Physiol Endocrinol Metab; 2005 Apr; 288(4):E741-7. PubMed ID: 15562250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Roles of adipose restriction and metabolic factors in progression of steatosis to steatohepatitis in obese, diabetic mice.
    Larter CZ; Yeh MM; Van Rooyen DM; Teoh NC; Brooling J; Hou JY; Williams J; Clyne M; Nolan CJ; Farrell GC
    J Gastroenterol Hepatol; 2009 Oct; 24(10):1658-68. PubMed ID: 19788606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advances in the relationship between obesity, inflammation, and insulin resistance.
    Bastard JP; Maachi M; Lagathu C; Kim MJ; Caron M; Vidal H; Capeau J; Feve B
    Eur Cytokine Netw; 2006 Mar; 17(1):4-12. PubMed ID: 16613757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.